

A Single Administration of the Atypical Psychedelic Ibogaine or its Metabolite Noribogaine Induces an Antidepressant-like Effect in Rats

Paola Rodríguez, Jessika Urbanavicius, Jose Pedro Prieto, Sara Fabius, Ana Laura Reyes, Vaclav Havel, Dalibor Sames, Cecilia Scorza, and Ignacio Carrera

ACS Chem. Neurosci., **Just Accepted Manuscript** • DOI: 10.1021/acscchemneuro.0c00152 • Publication Date (Web): 24 Apr 2020

Downloaded from pubs.acs.org on April 25, 2020

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

A Single Administration of the Atypical Psychedelic Ibogaine or its Metabolite Noribogaine Induces an Antidepressant-like Effect in Rats

Paola Rodríguez^{1,2}, Jessika Urbanavicius², José Pedro Prieto², Sara Fabius², Ana
Laura Reyes³, Vaclav Havel⁴, Dalibor Sames^{4*}, Cecilia Scorza^{2*}, Ignacio Carrera^{1*}

¹Laboratorio de Síntesis Orgánica, Departamento de Química Orgánica, Facultad de
Química - Universidad de la República, Montevideo, Uruguay


²Departamento de Neurofarmacología Experimental, Instituto de Investigaciones
Biológicas Clemente Estable, Montevideo, Uruguay

³Centro Uruguayo de Imagenología Molecular, Montevideo, Uruguay

⁴Department of Chemistry, Columbia University, New York, USA

***Corresponding authors:** Dalibor Sames, Cecilia Scorza and Ignacio Carrera

Keywords: psychedelic drugs, depression, preclinical test, serotonin, SERT



Abstract

Anecdotal reports and open label case studies in humans indicated that the psychedelic alkaloid ibogaine exerts profound anti-addictive effects. Ample preclinical evidence demonstrated the efficacy of ibogaine, and its main metabolite noribogaine, in substance use disorder rodent models. In contrast to addiction research, depression-relevant effects of ibogaine or noribogaine in rodents have not been previously examined. We have recently reported that the acute ibogaine administration induced a long-term increase of brain-derived neurotrophic factor mRNA levels in the rat prefrontal cortex, which led us to hypothesize that ibogaine may elicit antidepressant-like effects in rats. Accordingly, we characterized behavioral effects (dose and time-dependence) induced by the acute ibogaine and noribogaine (20 and 40 mg/kg, i.p.) administration in rats using the forced swim test (FST). We also examined the correlation between plasma and brain concentrations of ibogaine and noribogaine and the elicited behavioral response. We found that ibogaine and noribogaine induced a dose- and time-dependent antidepressant-like effect without significant changes of animal locomotor activity. Noribogaine's FST effect was short lived (30 minutes) and correlated with high brain concentrations (estimated $> 8 \mu\text{M}$ of free drug), while the ibogaine's antidepressant-like effect was significant at 3 hours. At this time point, both ibogaine and noribogaine were present in rat brain at concentrations that cannot produce the same behavioral outcome on their own (ibogaine $\sim 0.5 \mu\text{M}$, noribogaine $\sim 2.4 \mu\text{M}$). Our data suggests a polypharmacological mechanism underpinning the antidepressant-like effects of ibogaine and noribogaine.

INTRODUCTION

Ibogaine is the main indole alkaloid isolated from the root bark of the African shrub *Tabernanthe iboga* (Figure 1).¹⁻³ It is considered an atypical psychedelic drug capable of inducing waking dream-like states (oneirogenic effects) and vivid memory recall and replay.^{4, 5} Anecdotal reports and open label case studies with volunteers seeking detoxification from heroin and cocaine indicated ibogaine's ability to interrupt the drug dependence phenotype via rapid and lasting relief of drug withdrawal symptoms and cravings.⁶⁻⁸ Two recent open label observational clinical studies with subjects diagnosed with opioid dependence confirmed the earlier reports by showing a significant reduction of withdrawal symptoms (3 days post-treatment) and an improvement of quality of life (up to 12 months) after a single ibogaine therapeutic session.^{9, 10} In addition, a sustained antidepressant effect (evaluated at 1 and 12 months post-treatment) was recently reported,^{7, 10} consistent with other observations of ibogaine's attenuation of depressive symptoms in humans.^{5, 11, 12} The addiction-interrupting and antidepressant properties of ibogaine are of high interest considering the renaissance of psychedelic research and re-emerging use of psychedelic compounds as experimental therapeutics in neuropsychiatric disorders.¹³⁻¹⁵

Extensive preclinical work recapitulated the clinical effects of ibogaine in rodent models of substance use disorders (SUDs), including attenuation of self-administration of opioids, cocaine, nicotine, and alcohol, as well as a reduction of opioid withdrawal symptoms in opioid-dependent animals.^{16, 17} In addition, it has been shown that noribogaine, ibogaine's major metabolite (Figure 1), exhibits a similar potency and efficacy profile in rodent models of SUDs, leading to a mechanistic model where noribogaine contributes to the observed anti-SUD effects.¹⁸

We recently reported in rats that ibogaine induces a dose-dependent upregulation of glial cell-derived neurotrophic factor (GDNF) in specific brain regions of the rat brain related to the mesocorticolimbic and nigral dopaminergic circuits,¹⁹ an

1
2
3 effect which was previously proposed as a molecular mechanism underlying the
4 attenuation of drug self-administration and drug craving by ibogaine.^{20, 21} In addition, we
5 also found a large upregulation of brain-derived neurotrophic factor (BDNF) expression
6 in the prefrontal cortex after a single ibogaine administration, suggesting that ibogaine
7 may exert an antidepressant-like effect, since an increased BDNF signaling plays a
8 critical role in the antidepressant-like efficacy of selective serotonin uptake inhibitors
9 (SSRIs) in rodents.²²⁻²⁴ Also, we previously showed that ibogaine administration in rats
10 promoted an increase in wakefulness time and a long-lasting rapid eyes movement
11 (REM) sleep suppression, a profile which is also shared with SSRIs.²⁵ The increase in
12 wakefulness time in rodents has been also reported for rapidly acting antidepressants
13 such as ketamine and mGlu2/3 receptor antagonists.²⁶ Since it is well known that
14 ibogaine and noribogaine inhibit the plasma membrane serotonin transporter (SERT)
15 (noribogaine displaying approximately ten-fold greater inhibitory potency at SERT, IC₅₀
16 ~ 50-300 nM than ibogaine),²⁷⁻²⁹ we therefore postulated that ibogaine administration in
17 rats would exhibit antidepressant-like effects. In this manner, we hypothesized that the
18 above noted physiological effects and the BDNF upregulation would be, at least in part,
19 downstream consequences of the serotonin neurotransmission enhancement^{28, 30, 31}
20 generated by SERT inhibition. However, ibogaine can also block N-methyl-D-aspartate
21 receptors (NMDA-R),³² and NMDA-R non-competitive antagonists such as ketamine
22 and dizocilpine were also shown to exhibit antidepressant-like effect in rodents.³³⁻³⁶
23 Moreover, noribogaine was recently found to promote neuritogenesis in rat cortical
24 primary cultures, which could also contribute to a potential antidepressant-like effect in
25 rats.³⁷

26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51 In contrast to the large body of literature on SUD models, to our knowledge
52 the preclinical examination of antidepressant-like effects of ibogaine has not been
53 reported. Considering the clinical observations and the mechanistic considerations
54 mentioned above, we set out to examine the effects of ibogaine and noribogaine in the
55 forced swim test (FST) in rats, a widely used preclinical assay, that measures coping
56
57
58
59
60

strategy to an acute inescapable stress, with well-established responsiveness to a broad range of clinically efficacious antidepressants.³⁸⁻⁴⁰ In this manner, the present study was designed to characterize the behavioral effect (dose and time-dependence) induced by acute administration of ibogaine and noribogaine in rats using the FST. Additionally, the plasma and brain concentration of ibogaine and noribogaine were measured to associate the behavioral outcomes to the pharmacokinetic profiles of both drugs.




Figure 1. The psychoactive alkaloid ibogaine, its source, metabolism, and summary of clinical and preclinical effects. Illustration of different parts of *Tabernanthe iboga*. Ibogaine is isolated from the root bark. It is converted *in vivo* by the CYP2D6 isoform to its main active metabolite, noribogaine. In contrast to extensive examination of ibogaine in preclinical SUD models, antidepressant-like effects in rodents have not been investigated despite the clinical signals observed in anecdotal and open label studies.

RESULTS AND DISCUSSION

1
2
3 **Ibogaine elicits dose-dependent and time-dependent reduction in the**
4 **immobility time in the forced swim test.** The FST has been extensively used as a
5 behavioral screening test for antidepressant drugs with different mechanisms of
6 action.^{41, 42} When rats are subjected to the standard FST, two swimming sessions are
7 carried out 24 hours apart. The first one called “pre-test” has a duration of 15 minutes
8 and is aimed to stress and sensitize the animals to develop immobility in the second
9 session, the actual “test”, that lasts only 5 minutes (where the time animals spend
10 immobile, swimming or climbing is measured).^{38, 43} Antidepressant drugs are typically
11 administered 2-3x before the test swimming session (e.g. 24, 5 and 1 hour before the
12 test session) and induce significant reduction in the time animals spend immobile in
13 comparison to the vehicle control group (i.e., rats pursue more active escape
14 strategy).^{38, 40} We decided to examine the effect of acute administration of ibogaine in
15 the FST, since most of the previous pre-clinical studies using SUDs models were
16 carried out with a single intra-peritoneal (i.p.) administration of 20 mg/kg (I₂₀) or 40
17 mg/kg (I₄₀).¹⁷ Based on previous behavioral and pharmacokinetic (PK) studies using
18 i.p. administration,^{28, 44-46} and our own previous work,^{19, 25} we selected two time points
19 for the FST as 3 and 24 hours after ibogaine administration. At 3 hours, ibogaine and
20 noribogaine are expected to have pharmacologically and behaviorally relevant
21 concentrations in the rat brain, while the transient behavioral effects observed
22 immediately after the i.p. administration of I₄₀ (i.e. hypoactivity, tremor and
23 piloerection), which interfere with both the passive (immobility) and active (swimming
24 and climbing) behaviors, are absent at this time point. In contrast, at 24 hours ibogaine
25 would be no longer present in the brain and noribogaine would be at pharmacologically
26 irrelevant concentrations, allowing for examination of potential long-lasting effects
27 produced by both substances.

28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Figure 2A shows the effect of both doses of ibogaine in the FST evaluated 3 h
after the acute administration. For immobility time, one-way ANOVA revealed a
significant effect for treatment [$F_{(2,20)} = 4.11$, $P < 0.03$]. The Tukey post hoc test

1
2
3 showed that only I₄₀ was able to induce a significant decrease in the immobility time
4 compared to the control group ($P < 0.05$; Fig. 2A). This can be interpreted as an
5 antidepressant-like effect induced by I₄₀, and not due to nonspecific alterations on the
6 animal motor activity since One-way ANOVA showed no significant changes [$F_{(2,15)} =$
7 2.58 , $P = 0.11$] in the first 5 min of the animals motor activity evaluated 3 h after the
8 drug i.p. administration in the open field test (OFT, Fig. 2A,d). Remarkably, whereas a
9 wide range of clinically efficacious antidepressants typically require two or more
10 administrations to induce an antidepressant-like behavior in the rat FST, a single acute
11 I₄₀ administration elicited a statistically significant effect. In contrast, one-way ANOVA
12 did not reveal a significant effect for the treatment in the swimming [$F_{(2,20)} = 2.73$, $P =$
13 0.08] or climbing time [$F_{(2,20)} = 0.65$, $P = 0.53$]. Thus, neither active behavior was
14 significantly altered by ibogaine administration, however there was an upward trend in
15 the swimming readout. Figure 2B shows the effect of ibogaine in the FST evaluated 24
16 h after its i.p. administration. One-way ANOVA did not reveal a significant effect for the
17 treatment; neither for immobility [$F_{(2,17)} = 0.85$, $P = 0.44$], swimming [$F_{(2,17)} = 1.31$, $P =$
18 0.29] nor climbing time [$F_{(2,17)} = 0.53$, $P = 0.59$], although the swimming time showed a
19 qualitative trend toward a dose-dependent increase.

20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39 In order to correlate the behavioral results and the in vivo concentrations of
40 ibogaine and noribogaine, we carried out PK studies in brain (Figure 2C) and plasma
41 (See Supporting Information, SI) for both drugs after I₄₀ using the same route of
42 administration, evaluation time, and rat strain.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2. Ibogaine i.p. acute administration elicits dose-dependent and time-dependent antidepressant-like effects in rats. A) Effect of ibogaine (i.p. 20 and 40 mg/kg) evaluated in the FST (a-c) 3 h after the acute administration. The locomotor activity was recorded in a separate group of animals in the Open Field Test (OFT, d). The inset graph shows the distance traveled by the animals in the first 5 min, in accordance with the test session period of the FST. Only I₄₀ was able to induce a significant decrease in the immobility time compared to the control group ($P < 0.05$) without any significant change in locomotor activity. B) Effect of Ibogaine (i.p. 20 and 40 mg/kg) evaluated in the FST 24 h after the administration. No significant antidepressant-like effect was found for either dose. C) Pharmacokinetic profile showing ibogaine and noribogaine total concentrations in the rat brain after I₄₀ i.p. administration (concentrations of ibogaine and noribogaine at FST relevant time points are highlighted). Error bars represent mean \pm SEM. One-way ANOVA followed by Tukey's multiple comparisons test. * = $P < 0.05$ as compared to vehicle control. N = 7 - 8

Our results confirmed earlier PK reports in rats with regard to ibogaine's fast metabolism to noribogaine (which becomes the major species in plasma and brain

1
2
3 relative to ibogaine after ~ 45 min) and a high brain/plasma concentration ratio for both
4 drugs (ibogaine ~7.7 and noribogaine ~7.9). Nevertheless, there were some
5 differences between our data and that reported by Baumann et al²⁸: namely, our
6 results showed ibogaine's C_{max} being greater than the noribogaine's value, both in
7 plasma (1.5 fold) and in brain (2.2 fold) (for PK details see Supporting Information),
8 while the reversed scenario was found by the noted report. A possible explanation for
9 this discrepancy can be related to differences between whole blood (Baumann) and
10 plasma (our study) drug content and or a different strain of rats used.⁴⁷
11
12
13
14
15
16
17
18
19

20 Correlation of the PK values and the behavioral outcome suggests that the
21 response observed in the FST depends on the simultaneous presence of both ibogaine
22 and noribogaine in the brain. At 3 hours where a significant reduction in the immobility
23 was found, both drugs are circulating and evident in the brain tissue, where the mean
24 total concentration of 21 μ M was found for noribogaine and 9.9 μ M for ibogaine (Figure
25 2C). In contrast, at 24 hours, where no effect was observed in the FST, ibogaine was
26 not detectable while a residual amount of noribogaine (a mean value of 0.5 μ M, ~2% of
27 its C_{max}) was found in the brain. These results led to the next question of which
28 compound is responsible of the reduction of the immobility time at 3 hours after the I_{40}
29 treatment.
30
31
32
33
34
35
36
37
38
39
40
41
42

43 **Noribogaine induces a dose-dependent antidepressant-like effect in rats**
44 **but with a different time profile than ibogaine.** In order to study the contribution of
45 noribogaine to the behavioral effect induced by ibogaine, we examined the acute effect
46 of two doses of noribogaine, 20 mg/kg (N_{20}) and 40 mg/kg (N_{40}) in the FST. Since no
47 previous complete pharmacokinetic profiles were found in the literature for noribogaine
48 administered i.p. in rats, concentrations in plasma and brain were determined up to 24
49 hours for N_{40} (see Figure 3C) in order to select the time points for the FST study. The
50 pharmacokinetic data obtained is consistent with previous results in several species
51 showing high bioavailability and high brain penetration of noribogaine after direct
52
53
54
55
56
57
58
59
60

1
2
3 noribogaine administration (for key parameters, see Supporting Information).^{18, 27, 45, 46,}
4
5 ⁴⁸ Guided by the PK results, we carried out the FST at 0.5 h after noribogaine i.p.
6
7 administration, where the maximal brain concentration of noribogaine is achieved.
8
9 Additionally, to compare the results to those obtained after 3 h of i.p. ibogaine
10
11 administration, another experimental group was assayed at this time point after
12
13 noribogaine administration.
14

15
16 Results showed a significant and robust effect for the noribogaine treatment
17
18 on the time rats spent immobile after 0.5 hours of the i.p. administration [$F_{(2,18)} = 7.24$,
19
20 $P < 0.01$] (Figure 3A). Tukey post-hoc analysis showed a significant decrease in the
21
22 immobility time following N_{40} relative to vehicle-pretreated animals ($P < 0.01$) and the
23
24 lower dose N_{20} treatment ($P < 0.05$). In contrast, one-way ANOVA did not reveal
25
26 significant changes for swimming [$F_{(2,18)} = 2.44$, $P = 0.11$] or climbing behaviors [$F_{(2,18)}$
27
28 $= 1.85$, $P = 0.18$]. To evaluate potential behavioral confounds, the motor activity of
29
30 animals was examined (Figure 3A). One-way ANOVA indicated that no significant
31
32 changes in the animal locomotor performance were seen after N_{40} treatment [$F_{(2,12)} =$
33
34 0.60 , $P = 0.56$]. However, at 3 hours one-way ANOVA did not show significant changes
35
36 [$F_{(2,14)} = 0.77$, $P = 0.48$] in the immobility time of noribogaine-treated animals (Figure
37
38 3B). Further, neither swimming [$F_{(2,14)} = 0.65$, $P = 0.53$] nor climbing behavior [$F_{(2,14)} =$
39
40 0.48 , $P = 0.62$] were altered significantly by noribogaine (Figure 3B), although there
41
42 was a qualitative upward trend in the swimming time.
43
44

45
46 The PK results showed that at 0.5 hours a mean total concentration of 144
47
48 μM of the drug was reached in the brain. Since N_{20} was not effective at significantly
49
50 altering the behavioral patterns of the animals, assuming a linear concentration
51
52 dependence of the pharmacokinetic profile, total concentration of $\sim 72 \mu\text{M}$ of
53
54 noribogaine (half of 144 μM found for the C_{max} after N_{40} dose) was not sufficient to
55
56 produce a statistically significant effect, although a clear trend was observed (Figure
57
58 3A).
59
60




Figure 3. Noribogaine i.p. acute administration elicits dose-dependent and time-dependent antidepressant-like effects in rats. A) Effect of noribogaine (20 and 40 mg/kg) evaluated in the FST 0.5 h after the acute administration. The locomotor activity was recorded in a separate group of animals in the Open Field Test (OFT, d). The inset graph shows the distance traveled by the animals in the first 5 min, in accordance with the test session period of the FST. N₄₀ was able to induce a significant decrease in the immobility time relative to vehicle-pretreated animals ($P < 0.01$) and N₂₀ ($P < 0.05$), without any significant change in the distance traveled by the animals in the OFT. B) Effect of noribogaine (i.p. 20 and 40 mg/kg) evaluated in the FST 3 h after the acute administration. No antidepressant-like effect was found for either dose. C) Pharmacokinetics profile showing noribogaine concentrations in rat brain and plasma after N₄₀ i.p. administration (concentrations of noribogaine at FST relevant time points are highlighted). Error bars represent mean \pm SEM. One-way ANOVA followed by Tukey's multiple comparisons test. ** = $P < 0.01$ as compared to vehicle control and + = $P < 0.05$ as compared to noribogaine. N = 5 - 9

1
2
3 Similarly, the mean total brain concentration of 31 μM of noribogaine
4 determined at 3 hours is not enough to exert an antidepressant-like effect in the FST.
5 Also, the brain exposure to noribogaine over the period of 3 hours (AUC) after direct
6 noribogaine administration is much greater than the corresponding exposure after
7 ibogaine administration (and even the combined exposure to ibogaine and
8 noribogaine). Consequently, it is evident that noribogaine at exposures and
9 concentrations found in the rat brain 3 hours after i.p. administration of ibogaine (I_{40} , 21
10 μM , compare concentration values at 3 hours in Figure 2C and 3C) cannot alone drive
11 the antidepressant-like effect of ibogaine. Therefore, the next question was whether
12 ibogaine itself may actuate the antidepressant-like effect at the brain concentration at
13 or above that found 3 hours post drug administration (9.9 μM , I_{40} treatment). In order to
14 investigate this possible scenario, we examined the capacity of ibogaine to evoke an
15 antidepressant-like effect in the FST under conditions where metabolism to noribogaine
16 is minimized.

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35 **Ibogaine itself does not drive the antidepressant-like effect found in the**
36 **FST after ibogaine i.p. administration.** In this experiment, we administered ibogaine
37 through the intravenous route (i.v.) and evaluated the behavioral response in the FST.
38 As reported previously,²⁸ ibogaine i.v. administration greatly reduced its metabolism to
39 noribogaine because of liver first-pass avoidance, producing maximal ibogaine
40 concentration values one-minute post-injection, with only trace amounts of noribogaine
41 detected in blood. An ibogaine dose of 10 mg/kg i.v. used in that study, produced
42 significant transient behavioral impairments in rats, such as tremors, forepaw tapping,
43 abnormal postures, body sway and staggering-type locomotion that lasted for 30
44 minutes after administration. In order to avoid these behavioral impairments that could
45 interfere with the swimming or climbing performance, we tested the effect in the FST 1
46 minute after the i.v. administration of 1 mg/kg (I_1) and 5 mg/kg (I_5) of ibogaine (Figure
47
48
49
50
51
52
53
54
55
56
57
58
59
60

4A). In addition, concentration profiles for ibogaine and noribogaine in plasma and brain were determined after the higher dose (Figure 4B).

For immobility time, one-way ANOVA did not reveal a significant effect for the treatment [$F_{(2,20)} = 0.73$, $P = 0.49$]. In addition, neither swimming [$F_{(2,20)} = 1.81$, $P = 0.18$] nor climbing behavior [$F_{(2,20)} = 2.80$, $P = 0.08$] were altered significantly by either ibogaine i.v. doses. Nevertheless, a trend for reduction in the immobility time can be observed for the I_5 treatment. While it is likely that ibogaine would show a reduction in the immobility time at higher concentrations, it is not feasible to examine higher doses due to the above-mentioned behavioral side effects that are not compatible with animal performance in the FST. Examining brain PK results we confirmed that total noribogaine concentrations at 1 minute after injection were minimal ($\sim 0.07 \mu\text{M}$) and ibogaine total concentration was determined to be $23 \mu\text{M}$. Therefore, this brain level of ibogaine on its own was not able to produce a robust antidepressant-like effect in the FST. Comparing this result with the concentration of ibogaine detected 3 hours after i.p. I_{40} administration ($\sim 10 \mu\text{M}$), it seems that ibogaine itself cannot be responsible for reduction in the immobility time found in the FST during this experimental condition. There is a caveat to this interpretation related to the limited brain exposure to ibogaine after 1 minute, compared to the much greater exposure after 3 hours.




Figure 4. Ibogaine i.v. acute administration does not elicit an antidepressant-like effect in rats. A) Effect of ibogaine (i.v. 1 and 5 mg/kg) evaluated in the FST 1 minute after the acute administration. No antidepressant-like effect was found at either dose. B) Pharmacokinetics

1
2
3 profile showing ibogaine and noribogaine total concentrations in brain after I₅ i.v. administration.
4
5 Error bars represent mean ± SEM. One-way ANOVA followed by Tukey's multiple comparisons
6
7 test. Non significance was found. N = 7 - 9
8
9

10
11 **Interpretation: Both ibogaine and noribogaine are required for expression of**
12 **antidepressant-like effect in the FST after ibogaine i.p. administration.** Figure 5 A-
13
14 B summarizes the relationship between brain PK and behavioral data obtained in the
15
16 FST described previously. As can be seen, 23 μM of ibogaine found in the rat brains at
17
18 1 minute after i.v. I₅ administration, or 31 μM of noribogaine found after 3 h of i.p. N₄₀
19
20 administration, did not produce a statistically significant antidepressant-like response in
21
22 the FST. In contrast, when both drugs are present in the brain together at even lower
23
24 individual concentrations (9.9 μM ibogaine, 21 μM noribogaine) after 3 h i.p. I₄₀
25
26 administration, a significant reduction in the immobility time was observed, suggesting
27
28 a putative additive or synergistic effect produced by both drugs after I₄₀ administration.
29
30 Alternatively, these results could be rationalized by formation of an additional unknown
31
32 metabolite of ibogaine (that would be responsible for the antidepressant-like effect),
33
34 which would be formed after the i.p. but not intravenous administration.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 5. Correlation between pharmacokinetic data of ibogaine and noribogaine and the behavioral outcomes induced by both drugs in the FST at different times. Total concentrations of ibogaine and noribogaine found in rat brain after treatment A) without effect and B) with antidepressant-like effect. C) Binding of ibogaine and noribogaine to plasma proteins and brain tissue. D) Estimated free brain concentrations of ibogaine and noribogaine found in rat brain that correlate with an antidepressant-like effect. Error bars represent mean \pm SEM.

Regarding a possible neurochemical mechanism that explains the observed antidepressant-like effect, both drugs have been shown to inhibit SERT, noribogaine being approximately ten-times more potent than ibogaine (IC_{50} for noribogaine \sim 50-300 nM).²⁷⁻²⁹ We determined the plasma protein binding (in rat and human plasma) and rat brain tissue binding for both ibogaine and noribogaine, which allows for estimation of free plasma and free brain concentrations (Figure 5C and 5D). We estimate that at 3 hours post I_{40} free brain concentration of ibogaine is \sim 0.5 μ M and noribogaine 2.4 μ M, which is within a range relevant for SERT modulation. Thus, both drugs could inhibit 5-

1
2
3 HT reuptake and produce an enhancement in serotonergic transmission. *In vivo*
4 microdialysis studies in rats treated with ibogaine and noribogaine (1 and 10 mg/kg,
5 i.v.),^{28, 30, 31} showed that both drugs can induce significant increments in the
6 extracellular 5-HT content in the nucleus accumbens (NAcc) within the same range
7 (two to threefold compared to the control group, noribogaine being more potent),
8 comparable to effects induced by SSRIs. Similar results were obtained evaluating the
9 effect of ibogaine on 5-HT tone using *in vivo* microvoltammetric studies.⁴⁹ However,
10 additional neurochemical studies should be done to investigate the *per se* effect of
11 ibogaine or noribogaine and their combination at the same doses assayed here, on 5-
12 HT extracellular levels in other brain regions relevant to depression and mood
13 disorders (e.g., prefrontal cortex and hippocampus).
14
15

16
17
18
19
20
21
22
23
24
25
26 Finally, it is well documented that antidepressant drugs that selectively inhibit
27 noradrenaline uptake reduce immobility and increase climbing behavior without
28 affecting swimming, while antidepressants that inhibit serotonin uptake decrease
29 immobility but increase swimming behaviour.⁴² Neither of active behaviors were
30 significantly modified by ibogaine and noribogaine treatments used in this study,
31 although there were trends toward increasing the swimming time compared to the
32 control groups. This may reflect the abovementioned enhancement in the
33 serotonergic transmission owing to SERT inhibition and 5-HT re-uptake attenuation.
34 However, SERT modulation does not provide a comprehensive explanatory model as
35 the estimated free brain concentration of > 8 μM is required for noribogaine to elicit
36 significant FST effects when used alone: N_{20} was not significant, which is estimated to
37 give ~ 72 μM of noribogaine total tissue concentration ($\frac{1}{2}$ of 144 μM measured at 30
38 minutes), which is approximately equivalent to ~ 8 μM of free noribogaine brain
39 concentration). This estimated concentration range is > 20 greater than the *in vitro*
40 SERT inhibitory potency of noribogaine, the more potent SERT inhibitor of the two
41 compounds. The two-drug effect suggests additional target(s) at play. To further probe
42 this hypothesis, we carried out an additional experiment to test whether fluoxetine (a
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 classical SSRI) was able to induce an antidepressant-like effect in the FST after a
4
5 single dose of 40 mg/kg.
6
7
8

9 **Fluoxetine does not induce an antidepressant-like effect after a single dose**
10 **treatment.** To compare the efficacy of the iboga alkaloids used in this study to classical
11
12 SSRIs, we examined the effect elicited by fluoxetine, the prototypical SSRI, following
13
14 the same injection schedule and dose as those for noribogaine (Figure 6). In contrast
15
16 to noribogaine, fluoxetine (40 mg/kg) did not modify the immobility ($t_{10} = 0.62$, $P =$
17
18 0.55), swimming ($t_{10} = 0.32$, $P = 0.75$) or climbing time ($t_{10} = 0.28$, $P = 0.78$),
19
20 suggesting that noribogaine was more effective than fluoxetine at inducing an
21
22 antidepressant-like effect in this model. In order to obtain a significant reduction in the
23
24 immobility time, three doses of fluoxetine were required in our experimental setting
25
26 (See supporting information, consistent with previous reports).³⁸⁻⁴⁰ Fluoxetine is a
27
28 potent SERT blocker (low nM range)⁵⁰ and produces significant increases in
29
30 extracellular 5-HT as established by *in vivo* microdialysis studies.⁵¹ Our results suggest
31
32 substantial mechanistical differences between the iboga alkaloids and classical SSRIs.
33
34 It is known that ibogaine and noribogaine display differences in their interaction with
35
36 SERT in comparison to SSRIs and other common antidepressant drugs. While typical
37
38 SSRIs inhibit SERT in a competitive manner to 5-HT, generally stabilizing an outward-
39
40 facing conformation,⁵² ibogaine and noribogaine act non-competitively at the
41
42 transporter but display competitive binding towards SSRIs and stabilize an inward-
43
44 facing conformation.^{29, 53-55} Moreover, ibogaine and noribogaine have been classified
45
46 as pharmacochaperones, being able to rescue folding-deficient SERT mutants, an
47
48 effect not exhibited by SSRIs.⁵⁶ The functional and biological consequences for these
49
50 different interaction modes need further investigation. Alternatively, a
51
52 polypharmacological mode of action for the iboga alkaloids with respect to
53
54 antidepressant-like behavior represents a rational mechanistic model (e.g. NMDA-R
55
56 non-competitive antagonism, which has been described for ibogaine, can contribute to
57
58
59
60

its antidepressant-like effects). Although ibogaine and noribogaine trigger long-term plasticity effects, such as the expression upregulation of GDNF and BDNF shown in our recent report,¹⁹ the FST readouts in the present study did not indicate significant delayed behavioral effects. The potential long-term behavioral effects will be examined in future studies.

Efforts toward elucidating the neurochemical mechanisms behind the antidepressant-like effects (found in this study) and anti-SUD effects are ongoing in our laboratories, along with our medicinal chemistry program aimed at mapping the SAR of iboga-inspired analogs.⁵⁷




Figure 6. Fluoxetine 40 mg/kg i.p. acute administration does not elicit an antidepressant-like effect in rats. Acute effect of F₄₀ administration in the FST 30 minutes after the i.p. administration. No antidepressant effect was found. Error bars represent mean ± SEM. Unpaired Student *t*-test. Non significance was found. N = 6

CONCLUSIONS

In the present study we demonstrated for the first time that an i.p. administration of ibogaine and noribogaine in rats produce an acute antidepressant-like effect in a dose- and time-dependent manner. Using a single dose of 40 mg/kg, the effect was observed after 3 hours of administration of ibogaine, while noribogaine had a shorter duration (present 30 minutes after administration but lost at 3 hours). We

1
2
3 demonstrated that the antidepressant-like response produced after ibogaine i.p.
4 administration correlates with the presence of both ibogaine and noribogaine in rat
5 brain at concentrations that cannot produce the same behavioral outcome on their own,
6 indicating a potential additive/synergistic effect of both drugs or the existence of an
7 unknown active metabolite. Moreover, the effect found using a single dose of ibogaine
8 or noribogaine could not be reproduced by an equivalent dose of the classic SSRI
9 fluoxetine.
10
11
12
13
14
15
16

17
18 The translational utility of FST has been challenged owing to numerous
19 failures in clinical studies of compounds that showed positive results in FST and other
20 preclinical models of psychiatric disorders. However, drug development is a complex
21 process and the notion that the preclinical animal models are not predictive of clinical
22 outcomes may be an inaccurate generalization, according to recent surveys of the
23 available data.⁵⁸ The pharmacological validity or reverse translational validity of FST is
24 excellent as many different classes of clinically efficacious antidepressants are active in
25 this test. FST serves well for the purposes of this study: to gain mechanistic insights
26 about ibogaine's effects by reverse engineering the clinical signal to animal models. In
27 this context, our results indicate a potentially different neurochemical mechanism for
28 the iboga alkaloids as compared to classical SSRIs, and constitute the first step toward
29 identifying putative differences between classical antidepressant drugs (e.g., fluoxetine)
30 and ibogaine or noribogaine as a potential new class of antidepressant drugs.
31 Additional behavioral tests will be carried out to characterize the antidepressive-like
32 effect of ibogaine/noribogaine on other aspects of animal behavior that bear face
33 validity to human disease such as motivational and anhedonic readouts (e.g. chronic
34 unpredictable stress paradigm, sucrose preference test, learned helplessness test
35 among others).
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

55
56 Finally, our findings provide preclinical confirmation of the recently reported
57 antidepressant effects of ibogaine in opioid-dependent subjects. It is therefore
58
59
60

1
2
3 conceivable that the antidepressant efficacy may contribute to the anti-addictive
4 property of ibogaine and noribogaine.
5
6
7
8

9 **METHODS**

10 **Animals**

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Forced Swim Test and Open Field Test were carried out in the Instituto de Investigaciones Biológicas Clemente Estable (IIBCE, Uruguay) using adult male Wistar rats weighing 290-320 bred in the animal facility of the School of Medicine (Universidad de la República - Uruguay). All animals were acclimated in IIBCE facility for 5 days after they arrived. Animals were housed in groups of 4-5 in plastic cages (50 cm × 37.5 cm × 21 cm) and kept under controlled conditions (temperature $22 \pm 2^\circ\text{C}$, 12-h day-night cycle, lights on at 7:00 am) with food and water available *ad libitum*. All procedures were carried out in accordance to the Bioethics Committee Guidelines of the IIBCE and following the "Guide for use and care of Animals in the Laboratory" of the National Institute of Health, (NIH Publications N° 8023, revised 1978) and current ethical regulations under animal experimentation law N° 18.611 (Montevideo Uruguay).

Pharmacokinetic studies were conducted at Sai Life Sciences Limited, Pune, India, with approval of Institutional Animal Ethics Committee (IAEC) in accordance with requirement of The Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), India. Healthy male Wistar rats (8-12 weeks old) weighing between 280 to 300 g were procured from Global, India. Three rats were housed in each cage. Temperature and humidity were maintained at $22 \pm 3^\circ\text{C}$ and 30-70 %, respectively and illumination was controlled to give a sequence of 12 h light and 12 h dark cycle. All the animals were provided laboratory rodent diet (Envigo Research private Ltd, Hyderabad). Reverse osmosis water treated with ultraviolet light was provided *ad libitum*.

1
2
3 In all the experiments involving animals, adequate measures were taken into
4 account to minimize pain, discomfort or stress, and all efforts were made to use the
5 minimal number of animals necessary to obtain reliable scientific data.
6
7
8
9

10 11 **Drugs**

12 13 **Ibogaine·HCl**

14
15 The ibogaine used in this study was chemically synthesized in the Laboratorio
16 de Síntesis Orgánica, Facultad de Química – Universidad de la República, using
17 voacangine as starting material, which was extracted from the root bark of *Voacanga*
18 *africana* using a modification of a previously described procedure.⁵⁹ Briefly, 100 g of
19 grounded root bark of *Voacanga africana* was extracted with a 1% aqueous solution of
20 HCl (6 x 500 mL). The combined aqueous extracts were basified by adding
21 concentrated NH₄OH until pH 10 - 11. A brown precipitate was separated by
22 centrifugation and dried at 60°C for 24 h. This solid was taken in acetone and filtered to
23 discard root impurities. The solvent was evaporated in vacuo to afford a total alkaloid
24 extract of 3.5-4.0 g. Column chromatography (SiO₂, Hex:EtOAc:NH₄OH, 90:10:0.01)
25 allowed to obtain 1 g of pure voacangine which was analyzed by ¹H and ¹³C NMR (See
26 supporting information). Voacangine was decarboxylated as follows. To a solution of
27 voacangine in EtOH (0.45 M) in a double necked round bottomed flask, KOH in pellets
28 (10 equivalents) was added. The solution was heated to reflux until consumption of the
29 starting material was evident by thin layer chromatography (TLC) analysis. EtOH was
30 removed under reduced pressure, and the residue was dissolved at 0 °C in a round
31 bottomed flask using a 6% (v/v) aqueous solution of HCl (enough quantity to adjust pH
32 to 1). The system was then heated to reflux for five minutes. Once the starting material
33 consumption was evident by TLC analysis, the solution was carefully basified using
34 50% NaOH (pH 10 - 11). Precipitation of ibogaine as a white solid was observed. Ethyl
35 acetate was added, and the resulting biphasic system was transferred into a separation
36 funnel. The aqueous phase was extracted three times with EtOAc. The combined
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 organic layers were dried over Na₂SO₄, and the solvent was removed *in vacuo*.
4
5 Ibogaine free base was obtained with an 86% yield and was analyzed by ¹H and ¹³C
6
7 NMR (see supporting information). Crystallization from EtOH afforded a crystalline solid
8
9 which was converted to the corresponding hydrochloride by treatment with diethyl ether
10
11 saturated with HCl(g). Purity of ibogaine-HCl was determined by GC-MS analysis as
12
13 98.3 % (see supporting information). Dissolution of ibogaine-HCl to prepare the
14
15 samples for i.p. injection was carried out using warm saline/ethanol (9:1) vehicle that
16
17 was previously degassed by nitrogen bubbling.
18
19
20
21

22 **Noribogaine-HCl**

23
24 Noribogaine-HCl used for the FST studies was prepared by demethylation of ibogaine
25
26 in the Laboratorio de Síntesis Orgánica, Facultad de Química, Universidad de la
27
28 República. Briefly, under Nitrogen atmosphere, aluminium (3.0 equivalents, previously
29
30 washed with hexanes and dried overnight at 70 °C) was suspended in MeCN (enough
31
32 volume for a 0.3 M suspension), and iodine (3.0 equivalents) was added. The
33
34 suspension was heated under reflux until brownish color from iodine disappeared. The
35
36 resulting suspension was cooled to reach room temperature where a solution of 0.2 M
37
38 of ibogaine in MeCN (0.3 equivalents) was added. The suspension was heated under
39
40 reflux for at least 3 hours, until analysis by TLC (hexanes: ethyl acetate, 1:1 + 1%
41
42 NH₄OH) revealed complete consumption of ibogaine. After cooling to room
43
44 temperature, the suspension was added to aqueous HCl 5 % to destroy excess of
45
46 aluminium species. The resulting aqueous phase was basified by adding NaHCO₃, and
47
48 further extracted exhaustively with ethyl acetate. Combined organic layers were dried
49
50 using Na₂SO₄, and solvent distilled *under vacuo* to obtain a crude material, which was
51
52 purified using column chromatography (SiO₂, hexanes: ethyl acetate, 1:1 + 1%
53
54 NH₄OH) to obtain noribogaine as a pure white solid with 76 % yield. The free base was
55
56 converted to the corresponding hydrochloride by treatment with diethyl ether saturated
57
58 with HCl (g). Purity of noribogaine-HCl was determined by GC-MS analysis as 95.2 %
59
60

1
2
3 (see supporting information). Dissolution of noribogaine·HCl to prepare the samples for
4
5 i.p. injection was carried out using warm saline/ethanol (95:5) vehicle that was
6
7 previously degassed by nitrogen bubbling.
8
9

10
11 **Noribogaine·HCl** used for the PK studies was prepared at Columbia University by
12
13 Vaclav Havel.
14

15
16 A solution of voacangine (0.15 M) in CH₂Cl₂ (anhydrous) was cooled in ice bath (0 °C)
17
18 and treated with EtSH (4.5 equiv.) and BBr₃ (1M in CH₂Cl₂, 1.5 equiv., added dropwise
19
20 over 5 min). After all reagents were added, reaction mixture was allowed to warm to
21
22 room temperature. Progress of reaction (from small aliquots of reaction mixture
23
24 quenched with saturated NaHCO₃ solution) was monitored by TLC (hexanes: ethyl
25
26 acetate, 1:2), until no more starting material was observed (usually 1-2 h). Reaction
27
28 was quenched with a small amount of CH₃OH (until oily precipitates completely
29
30 dissolved) and poured to a saturated NaHCO₃ solution. The mixture was extracted 3x
31
32 with CH₂Cl₂ (until no more extraction was observed by TLC), combined extracts were
33
34 dried over Na₂SO₄ and concentrated *under vacuo*. Desmethyl-voacangine (typical
35
36 yield >95%) is obtained as an off-white foamy solid. Material is of sufficient purity to
37
38 use for the next step without further purification, if necessary, it can be purified by
39
40 column chromatography (SiO₂, hexanes: ethyl acetate, gradient of 20 to 30%).
41
42

43
44 Desmethyl-voacangine and either KOH or LiOH·H₂O (5 equiv.) were combined in a
45
46 mixture of EtOH and H₂O (2:1, 0.3 M). Reaction mixture was further heated to 80 °C
47
48 under argon atmosphere in a closed reaction vessel (a dark brown solution is formed).
49
50 After TLC indicated full conversion of starting material (hexanes: ethyl acetate, 1:2, <24
51
52 h) reaction mixture was cooled to room temperature and concentrated *under vacuo*.
53
54 Residue was dissolved in a small amount of H₂O (~15 - 20 mL for 1g of starting
55
56 material) and the solution was added to a hot 2M HCl (~30 mL for 1g of starting
57
58 material, pH must be ~1 after the solutions are combined) and the mixture was further
59
60 refluxed for 5 min under argon atmosphere. After cooling to RT, the mixture was

1
2
3 partially neutralized with 50% NaOH solution (to pH 5 - 6) and final adjustment was
4 done using excess solid NaHCO₃ (careful addition). Mixture was extracted repeatedly
5 with CH₂Cl₂ (until no more material was extracting as evidenced by TLC, if needed
6 CH₂Cl₂:iPrOH 9:1 mixture can be used to increase the speed of extraction). Combined
7 organic extracts were dried over Na₂SO₄, concentrated *under vacuo* and the dark
8 brown residue was pre-purified by a short column chromatography (SiO₂, hexanes:
9 ethyl acetate + 2% Et₃N, 1:2 to 1:1). Excess Et₃N was removed from isolated
10 noribogaine by repeated evaporation from MeOH/H₂O mixture. The still slightly colored
11 noribogaine free base was dissolved in CH₃OH (~10 - 15 mL for 1g of free base) and
12 the solution was acidified using aq. HCl (36%) to pH (~2, estimated by a pH paper).
13 Upon cooling to RT noribogaine·HCl started to crystallize from the solution. The
14 suspension was further cooled in freezer (-20 °C), the solid was collected by filtration
15 and washed repeatedly with cold CH₃OH to obtain an off-white (grey to light pink)
16 crystalline noribogaine·HCl (average yield of 60 - 65%) and a less pure methanolic
17 fraction. The crystalline noribogaine·HCl contains ~0.8 equiv. of CH₃OH bound in its
18 crystal structure which is not removed even after extensive drying *under vacuum*.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 Behavioral tests

40 41 42 43 Forced Swim Test (FST)

44
45 FST is one of the most commonly used assays for the study of depressive-
46 like behavior in rodents, since it examines certain aspects of despair and coping
47 behavior in rodents⁴³. Its sensitivity to a broad range of antidepressant drugs makes it a
48 suitable screening test³⁸. The procedure used for the FST was performed as previously
49 described.^{38, 42, 60} The apparatus consisted of a transparent cylindrical tank (50 cm
50 height and 20 cm diameter) filled with water (24 - 25 °C) to a depth of 34 cm (in order
51 to allow rats to swim or float without touching the bottom of the tank with their paws).
52
53
54
55
56
57
58
59
60 Two experimental swimming sessions within an interval of 24 h were carried out as

1
2
3 previously described.⁶⁰ Briefly, in the first pretest session, the animals were placed in
4 the tank for 15 min, immediately dried and returned to their home cage. During the test
5 session, the total time spent immobile (making only the movements necessary to
6 remain afloat), swimming (horizontal movements throughout the cylinder) and climbing
7 (vigorous and upward-directed movements of the forepaws along the cylinder wall)
8 were scored by a single, trained observer in real time during 5 min.^{42, 61} Sessions were
9 recorded for later analysis or confirmation when necessary.
10
11
12
13
14
15
16

17
18 These experimental groups were independently used for the behavioral studies:
19
20 1) animals received an intraperitoneal (i.p.) injection of ibogaine at 20 mg/kg, 40 mg/kg,
21 or vehicle (ethanol 5 % and saline; control group) and then exposed to the FST test
22 session 24 h and 180 minutes after the administration; 2) animals received an i.p.
23 injection of noribogaine at 20 or 40 mg/kg i.p. or vehicle (control group), and tested 30
24 or 180 min after the administration; 3) animals received an intravenously (i.v.) injection
25 of ibogaine at 1 and 5 mg/kg, or vehicle (control group) and exposed to the FST test
26 session immediately after the administration; 4) animals received an i.p. injection
27 Fluoxetine at 40 mg/kg (equivalent dose of noribogaine) only once or vehicle (saline).
28
29
30
31
32
33
34
35
36
37
38

39 **Open Field Test (OFT)**

40
41 This behavioral test was carried out in an independent group of animals to
42 discard the possibility that the behavioral changes observed in the FST were affected
43 by alterations in the locomotor activity. The OFT apparatus consisted of a square arena
44 (45 cm wide × 45 cm long × 40 cm high) with transparent plastic walls indirectly
45 illuminated (35 luxes) to avoid reflection and shadows. Locomotor activity was recorded
46 automatically by a camera located above the field connected to a computer equipped
47 with the Ethovision XT 12.0 software (Noldus, The Netherlands). We measured the
48 horizontal locomotor activity defined as the total distance moved in meters (m). After
49 recording the animal behavior, the OF was cleaned with alcohol 30 % before placing
50
51
52
53
54
55
56
57
58
59
60

1
2
3 the following rat.⁵³ In all the experiments rats were naive to the OF and were used only
4
5 once. All the experiments were performed between 9:00 and 14:00 h.
6
7
8

9 **Pharmacokinetic Experiments**

11 These experiments were conducted at Sai Life Sciences Limited. Plasma and
12 brain pharmacokinetic distribution of ibogaine and its metabolite noribogaine were
13 determined in three study groups of male Wistar rats following a single intravenous (5
14 mg/kg) and intraperitoneal (40 mg/kg) administration of ibogaine and intraperitoneal (40
15 mg/kg) administration of noribogaine. Solutions of nor/ibogaine were administered in
16 10% ethanol and 90% normal saline via intraperitoneal/intravenous route. The dosing
17 volume administered was 5 mL/kg for intravenous and 10 mL/kg for intraperitoneal
18 route. Blood samples (approximately 120 μ L) were collected under light isoflurane
19 anesthesia from retro orbital plexus from a set of three rats at specified time intervals.
20 Samples were collected into labeled micro-tubes, containing K₂EDTA solution (10 μ L of
21 20% K₂EDTA of solution per mL of blood) as an anticoagulant. Plasma was
22 immediately harvested from the blood by centrifugation at 4000 rpm for 10 min at 4 \pm 2
23 $^{\circ}$ C and stored below -70 \pm 10 $^{\circ}$ C until bioanalysis. Immediately after blood collection,
24 animals were euthanized with excess CO₂ and their brains were isolated at each time
25 point. Brains were rinsed three times in ice cold PBS (5 - 10 seconds rinse, using ~ 5 -
26 10 mL fresh PBS in disposable petri dish for each rinse) and dried on blotting paper.
27 Brain samples were homogenized using ice-cold phosphate buffer saline (pH 7.4) and
28 homogenates were stored below -70 \pm 10 $^{\circ}$ C until analysis. Total homogenate volume
29 was three times the tissue weight. See Supporting Information for detailed results.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54 **Statistical Analysis**

55 One-way analysis of variance (ANOVA) followed by post hoc Tukey's multiple
56 comparisons tests and Unpaired Student *t*-test were conducted to assess the main
57 effects of treatments in the FST and OFT. Calculations were carried out using
58
59
60

1
2
3 GraphPad Prism 7 software. All data are presented as mean \pm SEM, and significance
4
5 was determined at $P < 0.05$.
6
7
8

9 **ASSOCIATED CONTENT**

10 Supporting information contains analytical and NMR spectra of the drugs administered
11
12 to the animals, and details from the pharmacokinetic study and the FST. This
13
14 information is available free of charge via the Internet at <http://pubs.acs.org/>.
15
16
17
18
19

20 **AUTHOR INFORMATION**

21
22 Corresponding authors

23
24 **Dr. Ignacio Carrera.** Departamento de Química Orgánica, Facultad de Química –
25
26 Universidad de la República, Av. General Flores 2124, C.P. 11800, Phone:
27
28 +59829247881 Fax: +59829241906, E-mail: icarrera@fq.edu.uy
29

30
31 **Dra. Cecilia Scorza.** Departamento de Neurofarmacología Experimental, Instituto de
32
33 Investigaciones Biológicas Clemente Estable, Av. Italia 3318, C.P. 11600, Phone:
34
35 +59824871616, E-mail: cscorza@iibce.edu.uy
36

37
38 **Dr. Dalibor Sames.** Department of Chemistry, Columbia University, 3000 Broadway
39
40 MC3101, New York, NY 10027 USA, E-mail: sames@chem.columbia.edu
41
42

43 Author Contributions

44
45 Experiments were designed by P.R., D.S., C.S. and I.C. Experiments were performed
46
47 by P.R., J.U., J.P.P., S.F. A.L.R. and C.S. Data analyses were performed by P.R. C.S.
48
49 V.H. D.S. and I.C. Manuscript was written by P.R., V.H., D.S., C.S. and I.C.
50
51
52

53 **Funding Sources**

54
55 This research was supported by Agencia Nacional de Investigación e Innovación (ANII-
56
57 Uruguay, Fondo María Viñas FMV_1_2014_1_103488), Comisión Sectorial de
58
59 Investigación Científica (Universidad de la República, CSIC-Grupos I+D 1063),
60

1
2
3 Programa de Desarrollo de las Ciencias Básicas (PEDECIBA - Uruguay), and
4 Columbia University, New York, NY, USA. P.R. acknowledges ANII for a MSc and PhD
5 scholarships and V.H. acknowledges the Experientia Foundation Postdoctoral
6 Fellowship.
7
8
9
10
11
12

13 **ACKNOWLEDGEMENTS**

14
15
16 We thank Kevin Wulff for the original drawing of *Tabernanthe iboga* in Figure 1. We
17 also thank Dr. Madalee Gassaway Wulff for facilitating the commission of this drawing.
18
19 Dr. Andrew Kruegel, Dra. Mariana Pazos and Q.F. Bruno Gonzalez are acknowledged
20 for valuable discussions.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


REFERENCES

1. Alper, K. R. (2001) Ibogaine: a review, *Alkaloids Chem Biol* 56, 1-38.
2. Lavaud, C., and Massiot, G. (2017) The Iboga Alkaloids, *Prog Chem Org Nat Prod* 105, 89-136.
3. Wasko, M. J., Witt-Enderby, P. A., and Surratt, C. K. (2018) DARK Classics in Chemical Neuroscience: Ibogaine, *ACS Chem Neurosci* 9, 2475-2483.
4. Naranjo, C. (1973) *The Healing Journey*, Random House, New York.
5. Brown, T. K., Noller, G. E., and Denenberg, J. O. (2019) Ibogaine and Subjective Experience: Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use Disorder, *J Psychoactive Drugs* 51, 155-165.
6. Alper, K. R., Lotsof, H. S., Frenken, G. M., Luciano, D. J., and Bastiaans, J. (1999) Treatment of acute opioid withdrawal with ibogaine, *Am J Addict* 8, 234-242.
7. Mash, D. C., Duque, L., Page, B., and Allen-Ferdinand, K. (2018) Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes, *Front Pharmacol* 9, 529.
8. Schenberg, E. E., de Castro Comis, M. A., Chaves, B. R., and da Silveira, D. X. (2014) Treating drug dependence with the aid of ibogaine: a retrospective study, *J Psychopharmacol* 28, 993-1000.
9. Brown, T. K., and Alper, K. (2018) Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes, *Am J Drug Alcohol Abuse* 44, 24-36.
10. Noller, G. E., Frampton, C. M., and Yazar-Klosinski, B. (2018) Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study, *Am J Drug Alcohol Abuse* 44, 37-46.
11. Mash, D. C., Kovera, C. A., Pablo, J., Tyndale, R. F., Ervin, F. D., Williams, I. C., Singleton, E. G., and Mayor, M. (2000) Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures, *Ann N Y Acad Sci* 914, 394-401.
12. Mash, D. C., Kovera, C. A., Pablo, J., Tyndale, R., Ervin, F. R., Kamlet, J. D., and Hearn, W. L. (2001) Ibogaine in the treatment of heroin withdrawal, *Alkaloids Chem Biol* 56, 155-171.
13. Nichols, C. D., and Hendicks, P. S. (2020) *Handbook of the Behavioral Neurobiology of Serotonin*, Vol. 31 pp. 959-966, Elsevier B.V., Second Edition.
14. Chi, T., and Gold, J. A. (2020) A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses, *J Neurol Sci* 411, 116715.
15. Dos Santos, R. G., and Hallak, J. E. C. (2020) Therapeutic use of serotonergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms, *Neurosci Biobehav Rev* 108, 423-434.
16. Glick, S. D., Maisonneuve, I. M., and Szumlinski, K. K. (2001) Mechanisms of action of ibogaine: relevance to putative therapeutic effects and development of a safer iboga alkaloid congener, *Alkaloids Chem Biol* 56, 39-53.
17. Belgers, M., Leenaars, M., Homberg, J. R., Ritskes-Hoitinga, M., Schellekens, A. F., and Hooijmans, C. R. (2016) Ibogaine and addiction in the animal model, a systematic review and meta-analysis, *Transl Psychiatry* 6, e826.
18. Mash, D. C., Ameer, B., Prou, D., Howes, J. F., and Maillet, E. L. (2016) Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents, *J Psychopharmacol* 30, 688-697.
19. Marton, S., Gonzalez, B., Rodriguez-Bottero, S., Miquel, E., Martinez-Palma, L., Pazos, M., Prieto, J. P., Rodriguez, P., Sames, D., Seoane, G., Scorza, C., Cassina, P., and Carrera, I. (2019) Ibogaine Administration Modifies GDNF and BDNF Expression

- 1
2
3 in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits,
4 *Front Pharmacol* 10, 193.
- 5 20. He, D. Y., and Ron, D. (2006) Autoregulation of glial cell line-derived neurotrophic
6 factor expression: implications for the long-lasting actions of the anti-addiction drug,
7 Ibogaine, *FASEB J* 20, 2420-2422.
- 8 21. He, D.-Y., McGough, N. N. H., Ravindranathan, A., Jeanblanc, J., Logrip, M. L.,
9 Phamluong, K., Janak, P. H., and Ron, D. (2005) Glial Cell Line-Derived Neurotrophic
10 Factor Mediates the Desirable Actions of the Anti-Addiction Drug Ibogaine against
11 Alcohol Consumption, *J Neurosci* 25, 619-628.
- 12 22. Autry, A. E., and Monteggia, L. M. (2012) Brain-derived neurotrophic factor and
13 neuropsychiatric disorders, *Pharmacol Rev* 64, 238-258.
- 14 23. Rantamaki, T., Hendolin, P., Kankaanpaa, A., Mijatovic, J., Piepponen, P.,
15 Domenici, E., Chao, M. V., Mannisto, P. T., and Castren, E. (2007) Pharmacologically
16 diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB
17 and induce phospholipase-Cgamma signaling pathways in mouse brain,
18 *Neuropsychopharmacology* 32, 2152-2162.
- 19 24. Popova, N. K., Ilchibaeva, T. V., and Naumenko, V. S. (2017) Neurotrophic Factors
20 (BDNF and GDNF) and the Serotonergic System of the Brain, *Biochemistry (Mosc)* 82,
21 308-317.
- 22 25. Gonzalez, J., Prieto, J. P., Rodriguez, P., Cavelli, M., Benedetto, L., Mondino, A.,
23 Pazos, M., Seoane, G., Carrera, I., Scorza, C., and Torterolo, P. (2018) Ibogaine Acute
24 Administration in Rats Promotes Wakefulness, Long-Lasting REM Sleep Suppression,
25 and a Distinctive Motor Profile, *Front Pharmacol* 9, 374.
- 26 26. Witkin, J. M., Mitchell, S. N., Wafford, K. A., Carter, G., Gilmour, G., Li, J.,
27 Eastwood, B. J., Overshiner, C., Li, X., Rorick-Kehn, L., Rasmussen, K., Anderson, W.
28 H., Nikolayev, A., Tolstikov, V. V., Kuo, M. S., Catlow, J. T., Li, R., Smith, S. C.,
29 Mitch, C. H., Ornstein, P. L., Swanson, S., and Monn, J. A. (2017) Comparative Effects
30 of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor
31 Antagonist, and Ketamine, a Noncompetitive N-Methyl-d-Aspartate Receptor
32 Antagonist in Rodents: Evidence Supporting the Use of mGlu2/3 Antagonists, for the
33 Treatment of Depression, *J Pharmacol Exp Ther* 361, 68-86.
- 34 27. Staley, J. K., Ouyang, Q., Pablo, J., Hearn, W. L., Flynn, D. D., Rothman, R. B.,
35 Rice, K. C., and Mash, D. C. (1996) Pharmacological screen for activities of 12-
36 hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine,
37 *Psychopharmacology (Berl)* 127, 10-18.
- 38 28. Baumann, M. H., Rothman, R. B., Pablo, J. P., and Mash, D. C. (2001) In vivo
39 neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-
40 hydroxyibogamine (noribogaine), in rats, *J Pharmacol Exp Ther* 297, 531-539.
- 41 29. Jacobs, M. T., Zhang, Y. W., Campbell, S. D., and Rudnick, G. (2007) Ibogaine, a
42 noncompetitive inhibitor of serotonin transport, acts by stabilizing the cytoplasm-facing
43 state of the transporter, *J Biol Chem* 282, 29441-29447.
- 44 30. Mash, D. C., Staley, J. K., Baumann, M. H., Rothman, R. B., and Hearn, W. L.
45 (1995) Identification of a primary metabolite of ibogaine that targets serotonin
46 transporters and elevates serotonin, *Life Sci* 57, PL45-50.
- 47 31. Wei, D., Maisonneuve, I. M., Kuehne, M. E., and Glick, S. D. (1998) Acute iboga
48 alkaloid effects on extracellular serotonin (5-HT) levels in nucleus accumbens and
49 striatum in rats, *Brain Res* 800, 260-268.
- 50 32. Popik, P., Layer, R. T., and Skolnick, P. (1995) 100 years of ibogaine:
51 neurochemical and pharmacological actions of a putative anti-addictive drug,
52 *Pharmacol Rev* 47, 235-253.
- 53
54
55
56
57
58
59
60

- 1
2
3 33. Trullas, R., and Skolnick, P. (1990) Functional antagonists at the NMDA receptor
4 complex exhibit antidepressant actions, *Eur J Pharmacol* 185, 1-10.
- 5 34. Artigas, F. (2013) Future directions for serotonin and antidepressants, *ACS Chem*
6 *Neurosci* 4, 5-8.
- 7 35. Lener, M. S., Kadriu, B., and Zarate, C. A., Jr. (2017) Ketamine and Beyond:
8 Investigations into the Potential of Glutamatergic Agents to Treat Depression, *Drugs*
9 77, 381-401.
- 10 36. Zhang, K., and Hashimoto, K. (2019) An update on ketamine and its two
11 enantiomers as rapid-acting antidepressants, *Expert Rev Neurother* 19, 83-92.
- 12 37. Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C.,
13 Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., Duim, W. C., Dennis,
14 M. Y., McAllister, A. K., Ori-McKenney, K. M., Gray, J. A., and Olson, D. E. (2018)
15 Psychedelics Promote Structural and Functional Neural Plasticity, *Cell Rep* 23, 3170-
16 3182.
- 17 38. Porsolt, R. D., Anton, G., Blavet, N., and Jalfre, M. (1978) Behavioural despair in
18 rats: a new model sensitive to antidepressant treatments, *Eur J Pharmacol* 47, 379-391.
- 19 39. Porsolt, R. D., Le Pichon, M., and Jalfre, M. (1977) Depression: a new animal
20 model sensitive to antidepressant treatments, *Nature* 266, 730-732.
- 21 40. Porsolt, R. D., Bertin, A., Blavet, N., Deniel, M., and Jalfre, M. (1979) Immobility
22 induced by forced swimming in rats: effects of agents which modify central
23 catecholamine and serotonin activity, *Eur J Pharmacol* 57, 201-210.
- 24 41. Detke, M. J., Johnson, J., and Lucki, I. (1997) Acute and chronic antidepressant
25 drug treatment in the rat forced swimming test model of depression, *Exp Clin*
26 *Psychopharmacol* 5, 107-112.
- 27 42. Detke, M. J., Rickels, M., and Lucki, I. (1995) Active behaviors in the rat forced
28 swimming test differentially produced by serotonergic and noradrenergic
29 antidepressants, *Psychopharmacology (Berl)* 121, 66-72.
- 30 43. R., Y.-Y., M., F., A., H., and R., D. (2015) The forced swim test as a model of
31 depressive-like behavior, *J Vis Exp.* 97, 52587.
- 32 44. Hough, L. B., Pearl, S. M., and Glick, S. D. (1996) Tissue distribution of ibogaine
33 after intraperitoneal and subcutaneous administration, *Life Sci* 58, PL119-122.
- 34 45. Pearl, S. M., Hough, L. B., Boyd, D. L., and Glick, S. D. (1997) Sex differences in
35 ibogaine antagonism of morphine-induced locomotor activity and in ibogaine brain
36 levels and metabolism, *Pharmacol Biochem Behav* 57, 809-815.
- 37 46. Zubarán, C., Shoaib, M., Stolerman, I. P., Pablo, J., and Mash, D. C. (1999)
38 Noribogaine generalization to the ibogaine stimulus: correlation with noribogaine
39 concentration in rat brain, *Neuropsychopharmacology* 21, 119-126.
- 40 47. Baumann, M. H., Pablo, J., Ali, S. F., Rothman, R. B., and Mash, D. C. (2001)
41 Comparative neuropharmacology of ibogaine and its O-desmethyl metabolite,
42 noribogaine, *Alkaloids Chem Biol* 56, 79-113.
- 43 48. Kubiliene, A., Sveikata, A., Zevzikovas, A., Sadauskiene, I., and Ivanov, L. (2017)
44 Investigation into pharmacokinetic properties of active alkaloid ibogaine and its
45 metabolite noribogaine, *Acta Pol. Pharm.* 74, 1591-1597.
- 46 49. Broderick, P. A., Phelan, F. T., Eng, F., and Wechsler, R. T. (1994) Ibogaine
47 modulates cocaine responses which are altered due to environmental habituation: in
48 vivo microvoltammetric and behavioral studies, *Pharmacol Biochem Behav* 49, 711-
49 728.
- 50 50. Tavoulari, S., Forrest, L. R., and Rudnick, G. (2009) Fluoxetine (Prozac) binding to
51 serotonin transporter is modulated by chloride and conformational changes, *J Neurosci*
52 29, 9635-9643.
- 53
54
55
56
57
58
59
60

- 1
2
3 51. Qu, Y., Aluisio, L., Lord, B., Boggs, J., Hoey, K., Mazur, C., and Lovenberg, T.
4 (2009) Pharmacokinetics and pharmacodynamics of norfluoxetine in rats: Increasing
5 extracellular serotonin level in the frontal cortex, *Pharmacol Biochem Behav* 92, 469-
6 473.
7
8 52. Zeppelin, T., Ladefoged, L. K., Sinning, S., and B., S. (2019) Substrate and inhibitor
9 binding to the serotonin transporter: Insights from computational, crystallographic, and
10 functional studies, *Neuropharmacology* 161, 107548.
11 53. Bulling, S., Schicker, K., Zhang, Y. W., Steinkellner, T., Stockner, T., Gruber, C.
12 W., Boehm, S., Freissmuth, M., Rudnick, G., Sitte, H. H., and Sandtner, W. (2012) The
13 mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine
14 transporters, *J Biol Chem* 287, 18524-18534.
15 54. Coleman, J. A., Yang, D., Zhao, Z., Wen, P. C., Yoshioka, C., Tajkhorshid, E., and
16 Gouaux, E. (2019) Serotonin transporter-ibogaine complexes illuminate mechanisms of
17 inhibition and transport, *Nature* 569, 141-145.
18 55. Moller, I. R., Slivacka, M., Nielsen, A. K., Rasmussen, S. G. F., Gether, U., Loland,
19 C. J., and Rand, K. D. (2019) Conformational dynamics of the human serotonin
20 transporter during substrate and drug binding, *Nat Commun* 10, 1687.
21 56. Freissmuth, M., Stockner, T., and Sucic, S. (2018) SLC6 Transporter Folding
22 Diseases and Pharmacochaperoning, *Handb Exp Pharmacol* 245, 249-270.
23 57. Gassaway, M. M., Jacques, T. L., Kruegel, A. C., Karpowicz, R. J., Jr., Li, X., Li,
24 S., Myer, Y., and Sames, D. (2016) Deconstructing the Iboga Alkaloid Skeleton:
25 Potentiation of FGF2-induced Glial Cell Line-Derived Neurotrophic Factor Release by
26 a Novel Compound, *ACS Chem Biol* 11, 77-87.
27 58. Bernalov, A., Steckler, T., Altevogt, B., Koustova, E., Skolnick, P., Deaver, D.,
28 Millan, M. J., Bastlund, J. F., Doller, D., Witkin, J., Moser, P., O'Donnell, P., Ebert, U.,
29 Geyer, M. A., Prinssen, E., Ballard, T., and Macleod, M. (2016) Failed trials for central
30 nervous system disorders do not necessarily invalidate preclinical models and drug
31 targets, *Nat Rev Drug Discov* 15, 516.
32 59. Jenks, C. W. (2002) Extraction studies of *Tabernanthe iboga* and *Voacanga africana*,
33 *Nat Prod Lett* 16, 71-76.
34 60. Urbanavicius, J., Lagos, P., Torterolo, P., and Scorza, C. (2014) Prodepressive
35 effect induced by microinjections of MCH into the dorsal raphe: time course, dose
36 dependence, effects on anxiety-related behaviors, and reversion by nortriptyline, *Behav*
37 *Pharmacol* 25, 316-324.
38 61. Cryan, J. F., Markou, A., and Lucki, I. (2002) Assessing antidepressant activity in
39 rodents: recent developments and future needs, *Trends Pharmacol Sci* 23, 238-245.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



TOC Graphic

88x34mm (300 x 300 DPI)